Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a24a472ced28c892

Jump to content

// Workers AI · dad joke modeIs Pacific Edge Limited sharp? It has a cutting edge.

Add links
From Wikipedia, the free encyclopedia

Pacific Edge Limited
TypePublic
ASX & NZX: PEB
IndustryCancer diagnostics
Founded2001
Headquarters
Dunedin, New Zealand
Area served
United States, Australasia, Southeast Asia, and South America
Key people
Peter Meintjes (Group CEO), Glen Costin (President - APAC)
ProductsCxbladder suite of bladder cancer diagnostics tools
ServicesUrology
RevenueNZD$24.6m for the year ended 31 March 2025
Number of employees
Approx 100 globally
Websitepacificedgedx.com

Pacific Edge Limited, based in New Zealand, focuses on cancer diagnostics with a suite of bladder cancer diagnostic tools using genetic biomarkers. The company operates with a head office in Dunedin, New Zealand, and also has an office in Hershey, USA. It is listed on the Australian ASX and the New Zealand NZX main board stock exchange.[1]

History

[edit]

Pacific Edge, founded in August 2001,[2] utilizes genetic biomarkers in urine for cancer detection. Their approach is positioned as cost-effective compared to other diagnostic methods.[3] The company offers diagnostic services in New Zealand and the United States and has partnerships in Europe and Australia.

Listed on the New Zealand NZX index, Pacific Edge has undertaken capital raising initiatives, with rounds in 2013 and 2015 aimed at advancing the commercialization of their diagnostic tests in the United States.[4] In June 2020, Pacific Edge secured a commercial relationship with Kaiser Permanente, one of the largest health insurance providers in the U.S., for its bladder cancer tests.[5]

In May 2026, Pacific Edge announced a capital raising to address ongoing operating losses and declining cash reserves following the loss of Medicare reimbursement coverage in the United States for its Cxbladder tests.[6] The raise was initially structured to seek up to NZ$24 million through a placement and retail share offer. The company increased the size of the placement and ultimately raised NZ$25.4 million in new equity capital. The company stated that the proceeds would support ongoing operations, fund efforts to regain Medicare coverage, and support the commercial expansion of its diagnostic products.[7]

Products

[edit]

Pacific Edge offers a series of bladder cancer diagnostic tests known as Cxbladder. These tests include specialist subtype products designed for the detection of cancerous cells and to aid clinicians and oncologists in triage.[8] The tests are based on non-invasive urine samples, utilizing RNA and protein assays[citation needed]. Cxbladder is noted for its sensitivity and potential for earlier detection[citation needed] of bladder cancer, compared to other diagnostic methods such as cytology.[9][10][11][12]

Awards

[edit]

Pacific Edge has won a number of awards, including:

  • The NZ Innovators Award 2013[13]
  • NZBIO Biotech company of the year award 2014[14]
  • Medical Technology Association of New Zealand Innovation Award 2016[15]

References

[edit]
  1. ↑ "NZX -PEB". Retrieved 31 December 2015.
  2. ↑ "NZX Main Board - PEB Analysis". NZX. Retrieved 31 December 2015. Pacific Edge Limited (PEB) was formed in August 2001 following acquisition of intellectual property from the University of Otago.
  3. ↑ "Pacific Edge shares soar to new high". New Zealand Herald. 22 October 2013. ISSN 1170-0777. Retrieved 31 December 2015.
  4. ↑ "Pacific Edge seeks $35.3M to fund US growth". The New Zealand Herald. 26 June 2013. Retrieved 31 December 2015.
  5. ↑ "Kaiser Permanente Approves Commercial Use of Cxbladder - NZX, New Zealand's Exchange". www.nzx.com. Retrieved 25 June 2020.
  6. ↑ Pelletier, Nona (11 May 2026). "Pacific Edge aims to raise up to $24 million more after loss of US insurer". RNZ. Retrieved 14 May 2026.
  7. ↑ "Assessing Pacific Edge (NZSE:PEB) Valuation After NZ$25.4m Equity Raise For Cxbladder Medicare Push". simplywall.st. 13 May 2026. Retrieved 14 May 2026.
  8. ↑ "Suite of cancer products grows". Otago Daily Times. 29 December 2015. Retrieved 31 December 2015.
  9. ↑ Alan Wood (27 May 2015). "Pacific Edge's FY loss widens to $10.58m, plans to raise $35.3m". Stuff.co.nz. Retrieved 31 December 2015.
  10. ↑ MARTA STEEMAN (9 June 2015). "Singapore hospital to trial Pacific Edge's main bladder cancer detection product". Stuff.co.nz. Retrieved 31 December 2015.
  11. ↑ "Pacific Edge sales up; still no profit". Otago Daily Times. 27 November 2015. Retrieved 31 December 2015.
  12. ↑ "Pacific Edge gets US approval for Dunedin laboratory". The New Zealand Herald. 9 August 2015. Retrieved 31 December 2015.
  13. ↑ "Winners 2013". New Zealand Innovation Awards. Archived from the original on 20 January 2018. Retrieved 10 March 2026.
  14. ↑ Scarlett, Jared (13 May 2014). "Pacific Edge has the 'edge' at NZBIO Awards". Baldwins. Archived from the original on 4 March 2016. Retrieved 10 March 2026.
  15. ↑ "Pacific Edge Wins MTANZ Innovation Award for Cxbladder Technology". Pacific Edge. 30 May 2013. Retrieved 10 March 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pacific_Edge_Limited&oldid=1359641851"